Special Issue

Mitochondrial Bioenergetics: From Cellular Metabolism to Therapeutic Target

Message from the Guest Editor

This Special Issue will primarily focus on mitochondrial biology and bioenergetic function, which are implicated in the homeostasis of cellular metabolism and chronic disease pathogenesis. The discoveries and developments stemming from these studies will be extended to provide future research directions for disease treatment strategies. Mitochondria play a vital role in many biological systems that significantly adjust ATP synthase, adapt to cellular stress or lead to multiple diseases. Furthermore, the complex mitochondrial bioenergetic machinery correlates with the oxidative phosphorylation system (OXPHOS), which displays high flexibility to allow the remodeling of mitochondrial capacity to fulfill cellular elements. With the improvement of next-generation sequencing instruments and the advancement of bioinformatic analysis, there has been a great deal of emerging evidence of chronic diseases representing mitochondrial metabolism, ultrastructural integrity, microbiota metabolites targeting mitochondria, tRNA relative congenital disease, etc.

Guest Editor

Dr. Wei-Shiung Lian

1. Core Laboratory for Phenomics and Diagnostic, Department of Medical Research, Chang Gung University College of Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 83301, Taiwan
2. Center for Mitochondrial Research and Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 83301, Taiwan

Deadline for manuscript submissions

closed (31 August 2023)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/100747

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).